New activity is brewing for Ventyx Biosciences ( (VTYX) ). The company has submitted a Form DEFM14A to the SEC, indicating an upcoming shareholder vote. This form gives shareholders all the information they need to develop an informed vote. Read on to learn more about the proposed company action.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Ventyx Biosciences has called a special meeting of common stockholders for March 3, 2026, to vote on the adoption of a merger agreement signed on January 7, 2026, under which Eli Lilly and Company will acquire Ventyx through a merger with a Lilly subsidiary. If approved and completed, Ventyx stockholders will receive $14.00 in cash per common share, representing a roughly 62% premium to the company’s 30-day volume-weighted average trading price as of January 5, 2026, while preferred stockholders will receive $1,400.00 per preferred share, and stockholders who oppose the deal may instead seek court-determined appraisal under Delaware law. The Ventyx board has unanimously determined that the transaction is advisable and in the best interests of stockholders, is recommending that investors vote in favor of the merger, related executive compensation on an advisory basis, and a potential adjournment to solicit additional proxies, with the outcome set to determine the company’s future ownership and provide a liquidity event at a significant premium for shareholders.
The most recent analyst rating on (VTYX) stock is a Buy with a $15.50 price target. To see the full list of analyst forecasts on Ventyx Biosciences stock, see the VTYX Stock Forecast page.
Spark’s Take on VTYX Stock
According to Spark, TipRanks’ AI Analyst, VTYX is a Neutral.
The score is held back primarily by weak fundamentals typical of a development-stage biotech (no revenue, ongoing losses, and negative free cash flow), despite a low-debt balance sheet. Offsetting this, technicals show strong positive momentum with price well above key moving averages, and corporate events are supportive due to the announced all-cash acquisition by Eli Lilly, which reduces standalone business risk and increases visibility on value realization. Valuation remains constrained by losses (negative P/E) and no dividend support.
To see Spark’s full report on VTYX stock, click here.
More about Ventyx Biosciences
Ventyx Biosciences, Inc., based in San Diego, California, is a publicly listed biotechnology company. Its common and preferred shares are widely held by institutional and retail investors, and the company is governed by a board of directors that submits major corporate actions, such as mergers, to stockholder approval.
Average Trading Volume: 3,160,792
Technical Sentiment Signal: Buy
Current Market Cap: $1B
Find detailed analytics on VTYX stock on TipRanks’ Stock Analysis page.